Warren Eric reported option exercise involving 7,438 derivative units of Mineralys Therapeutics, Inc. at $0.00 for $0 on Sep 21, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Commercial Officer
Chief Commercial Officer
Filed Sep 22, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
7,438Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
230,563Direct
Trade date
Sep 21, 2026Option exercise
Filed
Sep 22, 2026, 6:48 PM ET1-day reporting delay
Accession
0001916048-26-000014Code M · Transaction 227854
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 21, 2026Sell7,438$28.12−$209,135.73Trade 227853
Sep 21, 2026Option exercise7,438$13.24$98,479.12Trade 227852
3 transaction rows in this filing. Joint filers share the same rows.

MLYS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MLYS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago −10%1d ago −4.7%
Returns since7d −17%30d −27%90d180d1y

Footnotes in full

F1: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.